A phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: A Children's Oncology Group Study

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 788-792

  Horton, Terzah M ^a   Arnes, Matthew M ^b   Reid, Joel M ^b   Krailo, Mark D ^c,d   Pendergrass, Thomas ^e   Mosher, Revonda ^f   Reaman, Gregory H ^f   Seibel, Nita L ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

ALL; AML; Lymphoblastic; Myelogenous; Pediatric; Taxol

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CANCER RELAPSE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INFECTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; TYPHLITIS; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; TREATMENT OUTCOME;

EID: 40449090448     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21310     Document Type: Article

References (17)

1. Crown J, O'Leary M. The taxanes: An update. Lancet 2000;355:1176-1178.
2. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002;3:755-766.
3. Bhalla K, Ibrado AM, Tourkina E, et al. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-568.
4. Consolini R, Pui CH, Behm FG, et al. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 1998;16:907-913.
5. Curtis JE, Minkin S, Minden MD, et al. A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: Preclinical cell culture studies. Br J Haematol 1996;95:354-363.
6. Colburn DE, Thomas DA, Giles FJ. Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia. Invest New Drugs 2003;21:109-111.
7. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: A pediatric oncology group study. J Clin Oncol 1993;11:2324-2329.
8. Rowinsky EK. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994;28:S18-S22.
9. Munker R, Kantarjian H, O'Brien S, et al. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol 1998;99:106-108.
10. Hayashi RJ, Blaney S, Sullivan J, et al. Phase 1 study of paclitaxel administered twice weekly to children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 2003;25:539-542.
11. Woo MH, Relling MV, Sonnichsen DS, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999;5:543-549.
12. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994;12:532-538.
13. Rowinsky EK, Burke PJ, Karp JE, et al. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 1989;49:4640-4647.
14. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-1239.
15. Seiter K, Feldman EJ, Traganos F, et al. Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Leukemia 1995;9:1961-1966.
16. Kris MG, O'Connell JP, Gralla RJ, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986;70:605-607.
17. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994;27:256-269.